What do the clinical features of positive nontuberculous mycobacteria isolates from patients with HIV/AIDS in China reveal? A systematic review and meta-analysis.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
01 Sep 2023
Historique:
medline: 4 9 2023
pubmed: 31 8 2023
entrez: 31 8 2023
Statut: epublish

Résumé

China has a high burden of nontuberculous mycobacterial (NTM) infections. Immunocompromised populations, such as those with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), are at a higher risk of being infected with NTM than immunocompetent individuals. Yet, there is a paucity of information on the clinical features of positive NTM isolates from patients with HIV/AIDS in China. To address this gap, we conducted a systematic review and meta-analysis of existing studies, comparing them against current expert consensus to provide guidance for clinical practice. Two researchers independently searched eight databases (SinoMed, China National Knowledge Infrastructure, Wanfang, VIP, Cochrane Library, PubMed, Embase, and Web of Science) from inception to 26 December 2022 to retrieve published Chinese- and English-language studies reporting clinical features of NTM-positive isolates among patients with HIV/AIDS in China. We included 28 studies with 1861 patients. The rate of positive NTM isolates detected from men among all patients was 87.3%. NTM species distribution was mainly Mycobacterium avium complex (64.3%), which was predominant in different regions. The five most common clinical symptoms were fever (68.5%), cough or expectoration (67.0%), appetite loss (49.4%), weight loss (45.5%), and superficial lymphadenectasis (41.1%). The prevalence of laboratory tests were as follows: albumin <35 g/L (55.6%), erythrocyte sedimentation rate >20 mm/h (91.4%), anaemia (59.0%), predominantly mild, CD4+ T cell count ≤50 pieces/μL (70.3%), and CD4+ T cell count 51-200 pieces/μL (22.1%). Lesion manifestations in thoracic imaging mainly included bilateral lung involvement (83.8%), showed stripe shadows (60.3%), patchy shadows (42.9%), nodules (40.6%), and bronchiectasis (38.6%). Accompanied signs included thoracic lymph node enlargement (49.5%). Seventy per cent of symptoms improved after treatment. Focusing on clinical symptoms, laboratory tests, and thoracic imaging helps with initial screening for NTM infections. Physicians should raise awareness of the diagnosis and treatment of Mycobacterium avium complex, providing guidance for experimental treatment, screening of priority populations for NTM infections, and prophylactic treatment of NTM disease. PROSPERO CRD42023388185.

Sections du résumé

Background UNASSIGNED
China has a high burden of nontuberculous mycobacterial (NTM) infections. Immunocompromised populations, such as those with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), are at a higher risk of being infected with NTM than immunocompetent individuals. Yet, there is a paucity of information on the clinical features of positive NTM isolates from patients with HIV/AIDS in China. To address this gap, we conducted a systematic review and meta-analysis of existing studies, comparing them against current expert consensus to provide guidance for clinical practice.
Methods UNASSIGNED
Two researchers independently searched eight databases (SinoMed, China National Knowledge Infrastructure, Wanfang, VIP, Cochrane Library, PubMed, Embase, and Web of Science) from inception to 26 December 2022 to retrieve published Chinese- and English-language studies reporting clinical features of NTM-positive isolates among patients with HIV/AIDS in China.
Results UNASSIGNED
We included 28 studies with 1861 patients. The rate of positive NTM isolates detected from men among all patients was 87.3%. NTM species distribution was mainly Mycobacterium avium complex (64.3%), which was predominant in different regions. The five most common clinical symptoms were fever (68.5%), cough or expectoration (67.0%), appetite loss (49.4%), weight loss (45.5%), and superficial lymphadenectasis (41.1%). The prevalence of laboratory tests were as follows: albumin <35 g/L (55.6%), erythrocyte sedimentation rate >20 mm/h (91.4%), anaemia (59.0%), predominantly mild, CD4+ T cell count ≤50 pieces/μL (70.3%), and CD4+ T cell count 51-200 pieces/μL (22.1%). Lesion manifestations in thoracic imaging mainly included bilateral lung involvement (83.8%), showed stripe shadows (60.3%), patchy shadows (42.9%), nodules (40.6%), and bronchiectasis (38.6%). Accompanied signs included thoracic lymph node enlargement (49.5%). Seventy per cent of symptoms improved after treatment.
Conclusions UNASSIGNED
Focusing on clinical symptoms, laboratory tests, and thoracic imaging helps with initial screening for NTM infections. Physicians should raise awareness of the diagnosis and treatment of Mycobacterium avium complex, providing guidance for experimental treatment, screening of priority populations for NTM infections, and prophylactic treatment of NTM disease.
Registration UNASSIGNED
PROSPERO CRD42023388185.

Identifiants

pubmed: 37651639
doi: 10.7189/jogh.13.04093
pmc: PMC10472018
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

04093

Informations de copyright

Copyright © 2023 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.

Références

Biosci Trends. 2018;12(5):515-516
pubmed: 30473561
J Craniomaxillofac Surg. 2011 Mar;39(2):91-2
pubmed: 21145753
Mil Med Res. 2020 Feb 29;7(1):7
pubmed: 32111253
Int J Mycobacteriol. 2016 Sep;5(3):288-293
pubmed: 27847012
Clin Infect Dis. 2016 Jun 15;62(12):1586-1594
pubmed: 27001796
Appl Environ Microbiol. 2019 Aug 14;85(17):
pubmed: 31253672
Drug Discov Today. 2018 Aug;23(8):1502-1519
pubmed: 29635026
PLoS One. 2022 Sep 26;17(9):e0275159
pubmed: 36155559
Zhonghua Jie He He Hu Xi Za Zhi. 2002 Jan;25(1):3-7
pubmed: 11953089
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Eur Respir J. 2020 Jul 7;56(1):
pubmed: 32636299
Multidiscip Respir Med. 2014 Sep 11;9(1):48
pubmed: 25264489
Infect Dis Poverty. 2022 Feb 7;11(1):16
pubmed: 35130974
Front Microbiol. 2018 Dec 03;9:2901
pubmed: 30559727
Science. 2016 Nov 11;354(6313):751-757
pubmed: 27846606
Chest. 2020 Jan;157(1):77-88
pubmed: 31374211
Chin Med J (Engl). 2019 Jun 5;132(11):1293-1297
pubmed: 30925547
Lancet HIV. 2019 Dec;6(12):e831-e859
pubmed: 31439534
Pathogens. 2023 Mar 23;12(4):
pubmed: 37111393
Medicine (Baltimore). 2016 May;95(21):e3802
pubmed: 27227959
PLoS One. 2013 Oct 25;8(10):e75915
pubmed: 24204583
BMC Infect Dis. 2021 Apr 24;21(1):381
pubmed: 33894767
Scand J Infect Dis. 2011 Jan;43(1):8-14
pubmed: 20849364
Lancet Infect Dis. 2022 Apr;22(4):507-518
pubmed: 34800394
J Gen Intern Med. 2020 Nov;35(Suppl 2):802-807
pubmed: 32808207
Clin Microbiol Rev. 2011 Apr;24(2):351-76
pubmed: 21482729
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
J Infect Dis. 2016 Sep 15;214(6):862-72
pubmed: 27559122
BMC Res Notes. 2016 Feb 17;9:109
pubmed: 26887928
Sci Rep. 2019 Mar 5;9(1):3476
pubmed: 30837537
Int J Tuberc Lung Dis. 2020 Sep 1;24(9):922-927
pubmed: 33156759
Lancet. 2018 Jul 28;392(10144):312-358
pubmed: 30032975
Int J Tuberc Lung Dis. 2011 Dec;15(12):1669-75
pubmed: 22118176
Int J Hyg Environ Health. 2019 May;222(4):628-634
pubmed: 30670342
Sci Rep. 2022 Nov 14;12(1):19523
pubmed: 36376401
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Apr 28;44(4):432-436
pubmed: 31113920
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64
pubmed: 29054853
Arch Bronconeumol. 2017 Oct;53(10):554-560
pubmed: 28433210
Tohoku J Exp Med. 2018;244(3):231-242
pubmed: 29563388

Auteurs

Jianwei Yuan (J)

Department of Infection, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

Yan Wang (Y)

Department of Infection, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

Lin Wang (L)

Department of Infection, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

Hongxia Wang (H)

Department of Infection, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

Yuan Ren (Y)

School of Public Health, Shanxi Medical University, Taiyuan, China.

Wenzhe Yang (W)

Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH